(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Aldeyra Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast ALDX's revenue for 2026 to be $2,027,545,613, with the lowest ALDX revenue forecast at $943,352,281, and the highest ALDX revenue forecast at $5,173,697,664. On average, 6 Wall Street analysts forecast ALDX's revenue for 2027 to be $3,059,457,495, with the lowest ALDX revenue forecast at $2,364,276,653, and the highest ALDX revenue forecast at $3,699,709,726.
In 2028, ALDX is forecast to generate $6,835,694,268 in revenue, with the lowest revenue forecast at $5,088,206,364 and the highest revenue forecast at $9,013,586,651.